Computer-aided detection of HER2 amplification status using FISH images: a preliminary study
暂无分享,去创建一个
David Gur | Rohit Bhargava | Bin Zheng | Xiao-Hui Wang | Urvashi Surti | U. Surti | B. Zheng | D. Gur | R. Bhargava | Xiao-Hui Wang
[1] D. Hayes,et al. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] D J O'Kane,et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. , 2000, The Journal of urology.
[3] Bin Zheng,et al. Automated detection and analysis of fluorescent in situ hybridization spots depicted in digital microscopic images of Pap-smear specimens. , 2009, Journal of biomedical optics.
[4] T. Lörch,et al. Automated fluorescent in situ hybridization (FISH) analysis of t(9;22)(q34;q11) in interphase nuclei , 2006, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[5] J. Klijanienko,et al. Detection and quantitation by fluorescence in situ hybridization (FISH) and image analysis of HER‐2/neu gene amplification in breast cancer fine‐needle samples , 1999, Cancer.
[6] D. Slamon,et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Dowsett,et al. Current Perspectives on HER2 Testing: A Review of National Testing Guidelines , 2003, Modern Pathology.
[8] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.
[9] Sunil R Lakhani,et al. The pathology of familial breast cancer: Immunohistochemistry and molecular analysis , 1999, Breast Cancer Research.
[10] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[11] David Gur,et al. An ellipse-fitting based method for efficient registration of breast masses on two mammographic views. , 2008, Medical physics.
[12] K. Shen,et al. Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer , 2008 .
[13] J. R. Reeves,et al. Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.
[14] Ioannis Pitas,et al. Automated evaluation of her-2/neu status in breast tissue from fluorescent in situ hybridization images , 2005, IEEE Transactions on Image Processing.
[15] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[16] Greg Yothers,et al. Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. , 2002, Journal of the National Cancer Institute.
[17] N. Personeni,et al. HER‐2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma , 2003, Cancer.
[18] L. Huo. HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial , 2007 .
[19] A. Zinsmeister,et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. , 1998, Blood.
[20] R. Bast,et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] G Konecny,et al. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. , 2000, Cancer treatment and research.
[22] Lyndsay N Harris,et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.